- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Parry becomes new AMDAI chairman
Hugh R. Parry has been named chairman of the board of AMD Alliance International (AMDAI), an international organization dedicated exclusively to macular disease.Parry, president and CEO of Prevent Blindness America, was appointed during the annual board meeting of AMDAI in New York on April 16, 2010.
Chicago-Hugh R. Parry has been named chairman of the board of AMD Alliance International (AMDAI), an international organization dedicated exclusively to macular disease.
Parry, president and CEO of Prevent Blindness America, was appointed during the annual board meeting of AMDAI in New York on April 16, 2010.
AMDAI is a consortium of 70 of the world's leading vision, seniors, and research organizations in 25 countries. Its goal is to bring knowledge, hope, and help to individuals and families around the globe affected by age-related macular degeneration (AMD). There are 30 million people affected by AMD worldwide and that number is predicted to triple over the next 10 years given the aging population.
“Eye diseases, such as macular degeneration, cross all borders,” said Parry. “I am honored to be chosen to chair this organization of dedicated individuals from around the world so that we may put forth a collaborative effort to help put an end to unnecessary vision loss.”
